Vidya Puthenpura, MD, MHS, FAAP
Assistant Professor of Pediatrics (Hematology/Oncology)Cards
About
Research
Publications
2025
“Techquity” in Pediatric, Adolescent, and Young Adult Oncology: Addressing Inequities Through Artificial Intelligence and Immersive Technologies
Puthenpura V, Hunter M, Marks A. “Techquity” in Pediatric, Adolescent, and Young Adult Oncology: Addressing Inequities Through Artificial Intelligence and Immersive Technologies. Pediatric Blood & Cancer 2025, 72: e31909. PMID: 40879575, DOI: 10.1002/pbc.31909.Peer-Reviewed Original ResearchConceptsEffective treatment environmentComplex care pathwaysYoung Adult OncologyQuality of lifePatient navigationCancer careCare deliveryHealth disparitiesCare pathwaysHealthcare providersUnderserved populationsPhysical rehabilitationPatient educationSocioeconomic statusPsychological supportAdult oncologyPain managementAYA patientsEquitable implementationCareCost barriersTreatment environmentYoung adultsSupportive careBridge gapsRisk of early death after acute leukemia diagnosis among adolescents and young adults
Berkman A, Andersen C, Puthenpura V, Short N, Merriman K, Swaminathan M, Cuglievan B, McCall D, DiNardo C, Nunez C, Jain N, Kadia T, Issa G, Gibson A, Garcia M, Livingston J, Parsons S, Hildebrandt M, Roth M. Risk of early death after acute leukemia diagnosis among adolescents and young adults. JNCI Cancer Spectrum 2025, 9: pkaf065. PMID: 40579211, PMCID: PMC12231595, DOI: 10.1093/jncics/pkaf065.Peer-Reviewed Original ResearchConceptsRisk of early deathSociodemographic factorsAcute leukemiaProportion of AYAsEarly deathOdds of early deathProportion of early deathsYoung adultsEnd Results registryStudy periodYear of diagnosisIncidence of early deathLeukemia typesT-lymphoblastic leukemia/lymphomaSocioeconomic statusHispanic ethnicityAYASignificant annual decreaseLogistic regressionAcute leukemia typesDeath proportionAcute promyelocytic leukemiaOlder ageRisk factorsMale sex
2024
Addressing Disparities in Adolescent and Young Adult Oncology: A Multifaceted Approach.
Puthenpura V. Addressing Disparities in Adolescent and Young Adult Oncology: A Multifaceted Approach. Journal Of The National Comprehensive Cancer Network 2024, 22: 508-510. PMID: 39236751, DOI: 10.6004/jnccn.2024.7062.Peer-Reviewed Original Research
2023
Identifying Gender and Racial Bias in Pediatric Fellowship Letters of Recommendation: Do Word Choices Influence Interview Decisions?
Boolchandani H, Chen L, Elder R, Osborn R, Phatak U, Puthenpura V, Sheares B, Tiyyagura G, Amster L, Lee S, Langhan M. Identifying Gender and Racial Bias in Pediatric Fellowship Letters of Recommendation: Do Word Choices Influence Interview Decisions? The Journal Of Pediatrics 2023, 265: 113843. PMID: 37995931, DOI: 10.1016/j.jpeds.2023.113843.Peer-Reviewed Original ResearchUse of Immersive Virtual Reality Spaces to Engage Adolescent and Young Adult Patients With Cancer in Therapist-Guided Support Groups: Protocol for a Pre-Post Study
Marks A, Garbatini A, Hieftje K, Puthenpura V, Weser V, Fernandes C. Use of Immersive Virtual Reality Spaces to Engage Adolescent and Young Adult Patients With Cancer in Therapist-Guided Support Groups: Protocol for a Pre-Post Study. JMIR Research Protocols 2023, 12: e48761. PMID: 37943596, PMCID: PMC10667982, DOI: 10.2196/48761.Peer-Reviewed Original ResearchINTERNATIONAL REGISTERED REPORT IDENTIFIERYoung adult patientsSupport groupsAdult patientsYoung adultsMean attendance rateSupport group interventionNon-Hispanic blacksNon-Hispanic whitesOverall retention rateNon-Hispanic AsiansRare disease populationPeer support groupsFacilitated support groupBone marrow failureMedian ageCommon diagnosisPreliminary efficacyHematologic malignanciesDisease populationLife measuresPatientsFinal intervention sessionTransgender femalesPsychosocial supportOUTC-08. IMPLEMENTING SOCIAL DETERMINANT OF HEALTH DATA COLLECTION FOR PEDIATRIC, ADOLESCENT AND YOUNG ADULT NEURO-ONCOLOGY PATIENTS IN THE CLINICAL TRIAL CONSORTIA SETTING: PROGRESS AND CHALLENGES
Puthenpura V, Bona K, Cooney T, Coven S, Davidson T, Fouladi M, Kline C, Leary S, Mueller S, Green A, Marks A. OUTC-08. IMPLEMENTING SOCIAL DETERMINANT OF HEALTH DATA COLLECTION FOR PEDIATRIC, ADOLESCENT AND YOUNG ADULT NEURO-ONCOLOGY PATIENTS IN THE CLINICAL TRIAL CONSORTIA SETTING: PROGRESS AND CHALLENGES. Neuro-Oncology 2023, 25: i37-i37. PMCID: PMC10260067, DOI: 10.1093/neuonc/noad073.145.Peer-Reviewed Original ResearchNeuro-oncology patientsMulticenter clinical trialClinical trialsSocial determinantsSocioeconomic statusClinical Trials ConsortiumLong-term complicationsAYA cancer patientsAdverse social determinantsSocioeconomic status dataAdverse SDOHSurvival disparitiesMultidisciplinary careTherapy adherenceToxicity incidenceCancer patientsTrial therapyPersonal socioeconomic statusOutcome disparitiesTrial designSDOHPatientsHealth equityHealth data collectionTrialsAdjuvant chemotherapy does not improve outcome in children with ovarian immature teratoma: A comparative analysis of clinical trial data from the Malignant Germ Cell International Consortium
Vieira A, Puthenpura V, Krailo M, Fallahazad N, Brougham M, Murray M, Frazier A, Lopes L, Pashankar F. Adjuvant chemotherapy does not improve outcome in children with ovarian immature teratoma: A comparative analysis of clinical trial data from the Malignant Germ Cell International Consortium. Pediatric Blood & Cancer 2023, 70: e30426. PMID: 37243320, DOI: 10.1002/pbc.30426.Peer-Reviewed Original ResearchConceptsOvarian immature teratomaOverall survivalImmature teratomaPostoperative chemotherapyBrazilian patientsStage IIAdjuvant chemotherapyUK cohortGrade 1 diseaseGrade 3 patientsReceipt of chemotherapyMainstay of therapyValue of chemotherapyPrimary outcome measureClinical trial dataIT patientsEntire cohortUK patientsRelapse riskBrazilian cohortOutcome measuresPractice variationChemotherapyPatientsStage IPersonality Changes and Staring Spells in a 12-Year-Old Child: A Case Report Incorporating ChatGPT, a Natural Language Processing Tool Driven by Artificial Intelligence (AI)
Puthenpura V, Nadkarni S, DiLuna M, Hieftje K, Marks A. Personality Changes and Staring Spells in a 12-Year-Old Child: A Case Report Incorporating ChatGPT, a Natural Language Processing Tool Driven by Artificial Intelligence (AI). Cureus 2023, 15: e36408. PMID: 37090271, PMCID: PMC10115215, DOI: 10.7759/cureus.36408.Peer-Reviewed Original ResearchLow-grade gliomasIntracranial tumorsPersonality changesTreatment of LGGCentral nervous system tumorsMain presenting featuresBroad differential diagnosisNervous system tumorsPresenting featuresPediatric patientsCase reportSystem tumorsFavorable outcomeEndocrine conditionsMain symptomsDifferential diagnosisIntracranial neoplasmsBrain tumorsGrade gliomasEarly identificationSymptomsTumorsOlder childrenCommon typeNatural language processing toolsWords Used in Letters of Recommendation for Pediatric Residency Applicants: Demographic Differences and Impact on Interviews
Boolchandani H, Osborn R, Tiyyagura G, Sheares B, Chen L, Phatak U, Puthenpura V, Elder R, Lee S, Amster L, Langhan M. Words Used in Letters of Recommendation for Pediatric Residency Applicants: Demographic Differences and Impact on Interviews. Academic Pediatrics 2023, 23: 1614-1619. PMID: 36889506, DOI: 10.1016/j.acap.2023.02.012.Peer-Reviewed Original ResearchConceptsLetters of recommendationLetter writersCommunal termsNatural language processing applicationsLanguage processing applicationsApplicant genderInterview statusCommunal wordsWritersLanguageAgentic termsWordsGenderLetterSenior academic ranksRaceTextAgenciesEquitable approachResidency candidatesWomenSignificant associationEthnicitySignificant differencesInterviewsLoss to follow‐up of minorities, adolescents, and young adults on clinical trials: A report from the Children's Oncology Group
Puthenpura V, Ji L, Xu X, Roth M, Freyer D, Frazier A, Marks A, Pashankar F. Loss to follow‐up of minorities, adolescents, and young adults on clinical trials: A report from the Children's Oncology Group. Cancer 2023, 129: 1547-1556. PMID: 36813754, PMCID: PMC10357561, DOI: 10.1002/cncr.34701.Peer-Reviewed Original ResearchConceptsClinical trial participantsNon-Hispanic blacksTrial participantsHazard ratioOncology GroupClinical trialsMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelChildren's Oncology Group trialsProportional hazards regression modelsYoung adultsAdjusted hazard ratioChildren's Oncology GroupLong-term complicationsLong-term outcomesLog-rank testHazards regression modelsPediatric clinical trialsCancer clinical trial participantsLow socioeconomic status areasLong-term survivalEthnic minority patientsQuality of lifeLow socioeconomic statusNon-Hispanic whites
Clinical Trials
Current Trials
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
HIC ID2000034320RoleSub InvestigatorPrimary Completion Date06/30/2027Recruiting ParticipantsA Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
HIC ID2000028692RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting ParticipantsA Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
HIC ID2000028880RoleSub InvestigatorPrimary Completion Date09/30/2027Recruiting ParticipantsA Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
HIC ID2000026862RoleSub InvestigatorPrimary Completion Date06/30/2029Recruiting ParticipantsA Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
HIC ID2000023595RoleSub InvestigatorPrimary Completion Date09/30/2026Recruiting Participants
Clinical Care
Overview
Vidya Puthenpura, MD, MHS, is a pediatric hematologist and oncologist who says she seeks a strong connection with her patients and families.
“I love my patients and I’m really attached to them,” she says. “A cancer diagnosis is hard and one thing that can ease their mind is knowing that I am there for them through both the good and tough times. I find I do my best work when I am emotionally connected to what I do, and having that connection with children and their families is so rewarding.”
Dr. Puthenpura originally thought she wanted to be an engineer, but a volunteer experience she had at a pediatric cancer institute convinced her she wanted to be a doctor and work with kids.
“The children were so amazing and motivated and I knew I wanted to help them get better,” she says. “In medical school, I explored a few different specialties, but I kept coming back to hematology and oncology. I love that you have continuity of care because you spend so much time with patients and make a connection. I also loved that the field is constantly growing and changing with innovations.”
Dr. Puthenpura treats a variety of conditions, but her personal area of interest is in pediatric brain tumors.
“We have an amazing multidisciplinary team. Our goal is to focus on the entire family, including caregivers and siblings,” she says. “We tailor how we explain what is going on to a child based on their age and level of maturity. And for parents, we try to explain things in a thorough manner because we need them to understand what is going on. For some, we break it down into parts, whereas other parents come in armed with information about clinical trials.”
Her research examines health disparities. “Adolescents and young adults in the U.S. who have brain tumors and are minorities and live in rural areas are disadvantaged—and tend to have decreased survival rates and access to clinical trials compared to non-Hispanic, white youth,” she says. “These issues are important, and I’m happy to see them coming to the limelight more.”
Clinical Specialties
Fact Sheets
Pediatric Brain and Spinal Cord Tumors
Learn More on Yale MedicineNeuroblastoma
Learn More on Yale MedicineAtypical Teratoid/Rhabdoid Tumors
Learn More on Yale MedicineSpinal Tumors
Learn More on Yale Medicine
Yale Medicine News
News
News
- December 05, 2025Source: Greenwich Sentinel
Inside the Fight: Yale’s Pediatric Neuro-Oncologists and the Families They Serve
- October 15, 2025Source: News 12 CT
What families should know about childhood cancer
- January 07, 2025Source: News12 CT
Greenwich family donates $27,550 to support childhood cancer patients
- December 03, 2024Source: People Are Saying Podcast
People Are Saying: Ep. 6 - Mairead Finn and Meg McQuillan
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.